Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?

Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 2 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.

Integral Molecular Enables Membrane Protein Antibody Discovery

With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.

Membrane Protein Solutions

60+ Publications Including Cell, Science & Nature

Trusted by 100+ Companies

Ready to Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let's talk about how we can help you.
Or call (215) 966-6061